2.要約中間連結財務諸表及び主な注記

(1)要約中間連結財政状態計算書

 

 

 

 

 

(単位:百万円)

 

 

 

前連結会計年度末

(2026年3月31日)

 

当中間連結会計期間末

(2026年9月30日)

資産

 

 

 

 

 

流動資産

 

 

 

 

 

現金及び現金同等物

 

 

76,592

 

72,849

営業債権及びその他の債権

 

 

46,157

 

48,462

棚卸資産

 

 

51,595

 

53,251

その他の金融資産

 

 

2,414

 

2,750

その他の流動資産

 

 

6,326

 

6,769

流動資産合計

 

 

183,086

 

184,083

非流動資産

 

 

 

 

 

有形固定資産

 

 

34,954

 

35,705

無形資産

 

 

48,242

 

53,990

使用権資産

 

 

2,588

 

3,336

その他の金融資産

 

 

67,356

 

48,713

繰延税金資産

 

 

6,957

 

6,957

その他の非流動資産

 

 

3,172

 

3,102

非流動資産合計

 

 

163,272

 

151,806

資産合計

 

 

346,359

 

335,890

 

 

 

 

 

 

 

 

 

 

 

 

 

(単位:百万円)

 

 

 

前連結会計年度末

(2026年3月31日)

 

当中間連結会計期間末

(2026年9月30日)

負債及び資本

 

 

 

 

 

負債

 

 

 

 

 

流動負債

 

 

 

 

 

営業債務及びその他の債務

 

 

26,132

 

24,311

その他の金融負債

 

 

273

 

302

リース負債

 

 

913

 

1,406

未払法人所得税

 

 

6,979

 

4,257

その他の流動負債

 

 

7,806

 

8,169

流動負債合計

 

 

42,105

 

38,447

非流動負債

 

 

 

 

 

その他の金融負債

 

 

235

 

235

リース負債

 

 

1,654

 

1,921

退職給付に係る負債

 

 

4,557

 

4,215

繰延税金負債

 

 

5,875

 

265

その他の非流動負債

 

 

59

 

57

非流動負債合計

 

 

12,382

 

6,695

負債合計

 

 

54,488

 

45,142

資本

 

 

 

 

 

資本金

 

 

5,174

 

5,174

資本剰余金

 

 

4,547

 

4,568

利益剰余金

 

 

246,691

 

258,162

自己株式

 

 

△2,440

 

△2,422

その他の資本の構成要素

 

 

37,578

 

24,943

親会社の所有者に帰属する持分合計

 

 

291,551

 

290,426

非支配持分

 

 

319

 

321

資本合計

 

 

291,871

 

290,747

負債及び資本合計

 

 

346,359

 

335,890

 

 

E0093145160日本新薬株式会社Nippon Shinyaku Co.,Ltd.四半期第7号参考様式 [IFRS](連結)(一般2Q)IFRStrueCTE2026-04-012026-09-30HY2027-03-312025-04-012025-09-302026-03-311falsefalsefalse451602025-04-012025-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-04-012025-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-04-012025-09-30jpigp_cor:NonControllingInterestsIFRSMember451602025-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-09-30jpigp_cor:ShareCapitalIFRSMember451602025-09-30jpigp_cor:CapitalSurplusIFRSMember451602025-09-30jpigp_cor:RetainedEarningsIFRSMember451602025-09-30jpigp_cor:TreasurySharesIFRSMember451602025-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-09-30jpigp_cor:NonControllingInterestsIFRSMember451602026-04-012026-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602026-04-012026-09-30jpigp_cor:ShareCapitalIFRSMember451602026-04-012026-09-30jpigp_cor:CapitalSurplusIFRSMember451602026-04-012026-09-30jpigp_cor:RetainedEarningsIFRSMember451602026-04-012026-09-30jpigp_cor:TreasurySharesIFRSMember451602026-04-012026-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602026-04-012026-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602026-04-012026-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602026-04-012026-09-30jpigp_cor:NonControllingInterestsIFRSMember451602026-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602026-09-30jpigp_cor:ShareCapitalIFRSMember451602026-09-30jpigp_cor:CapitalSurplusIFRSMember451602026-09-30jpigp_cor:RetainedEarningsIFRSMember451602026-09-30jpigp_cor:TreasurySharesIFRSMember451602026-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602026-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602026-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602026-09-30jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-09-30jpcrp_cor:ReportableSegmentsMember451602025-04-012025-09-30tse-scediffr-45160:MedicineReportableSegmentMember451602025-04-012025-09-30tse-scediffr-45160:FunctionalFoodsReportableSegmentMember451602025-04-012025-09-30jpcrp_cor:ReconcilingItemsMember451602026-04-012026-09-30tse-scediffr-45160:MedicineReportableSegmentMember451602026-04-012026-09-30tse-scediffr-45160:FunctionalFoodsReportableSegmentMember451602026-04-012026-09-30jpcrp_cor:ReconcilingItemsMember451602026-04-012026-09-30jpcrp_cor:ReportableSegmentsMember451602025-03-31451602026-03-31451602025-04-012025-09-30451602025-09-30451602026-04-012026-09-30451602026-09-30451602026-11-13451602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-03-31jpigp_cor:ShareCapitalIFRSMember451602025-03-31jpigp_cor:CapitalSurplusIFRSMember451602025-03-31jpigp_cor:RetainedEarningsIFRSMember451602025-03-31jpigp_cor:TreasurySharesIFRSMember451602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-03-31jpigp_cor:NonControllingInterestsIFRSMember451602026-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602026-03-31jpigp_cor:ShareCapitalIFRSMember451602026-03-31jpigp_cor:CapitalSurplusIFRSMember451602026-03-31jpigp_cor:RetainedEarningsIFRSMember451602026-03-31jpigp_cor:TreasurySharesIFRSMember451602026-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602026-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602026-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602026-03-31jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-04-012025-09-30jpigp_cor:ShareCapitalIFRSMember451602025-04-012025-09-30jpigp_cor:CapitalSurplusIFRSMember451602025-04-012025-09-30jpigp_cor:RetainedEarningsIFRSMember451602025-04-012025-09-30jpigp_cor:TreasurySharesIFRSMember451602025-04-012025-09-30jpigp_cor:OtherComponentsOfEquityIFRSMemberiso4217:JPYxbrli:pureiso4217:JPYxbrli:shares